Investor Relations

Myriad Genetics is a leading healthcare company focused on the development and marketing of novel molecular diagnostic products.

We believe that the future of medicine lies in a shift from a treatment paradigm to a prevention paradigm. By understanding the genetic basis of disease, we believe we will improve our ability to determine which patients are subject to a greater risk of developing disease and who therefore would benefit from preventive therapies. Our goal is to provide physicians with critical information to help guide the healthcare management of their patients to prevent disease, delay the onset of disease, or catch disease at an earlier stage when it typically is more treatable.

To this end, we employ a number of proprietary technologies that permit us to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. We use this information to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy and tailor a patient's drug dose to ensure optimal treatment (personalized medicine), and assess a patient's risk of disease progression and disease recurrence (prognostic medicine). We have launched seven commercial molecular diagnostic products, including four predictive medicine and three personalized medicine products. We market these products through our own 250-person sales force in the United States and we have entered into marketing collaborations with other organizations in selected foreign countries.

News Releases

Aug 31, 2010
Myriad Genetics to Present at the UBS Global Life Sciences Conference and the Fifth Annual JMP Securities Healthcare Conference

Aug 31, 2010
Myriad Announces Additional Stock Repurchase Program

View all releases »

Events & Presentations

Sep 14, 2010 at 9:45 AM ET
Morgan Stanley Global Healthcare Conference

Sep 15, 2010 at 10:20 AM ET
Stifel Nicolaus Healthcare Conference

View all events & presentations »













Stock Information
Ticker:MYGN
Exchange: NASDAQ
Last Trade: $15.95
Change: down 0.15
Volume: 112,700

Sep 3, 2010  10:51 AM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.